|
|
| |
|
Key Technologies Required for
Transcription Factors Oligonucleotide Drug
R&D
|
• Transcription factor drug target prediction technology based on KeyGen Human
Genomic Regulatory Database (HGRD)
The first important thing for oligonucleotide drug R&D targeting transcription factor is to predict which transcription factor is the suitable drug target for
a kind of specific kind of cancer. KeyGen has grasped the drug target prediction
technology based on the tool of Human Genomic Regulatory Database (HGRD) with self
owned intellectual property. This database has correlate the transcription factors
with specific cancer and provide the information of downstream oncogenes which are
regulated by the specific transcription factor.
• Transcription factors detection technology
KeyGen has developed the technology of transcription factor detection which
has enabled the analysis of theoretical designed oligonucleotide in practical condition.
• Oligonucleotide new drugs designing technology
KeyGen has developed the technology of oligonucleotide designing. This technology
is efficient and cost saving. Over 90 percent of the designed oligonucleotides have been proved to be active by in vitro anti-cancer screening and target the specific
transcription factor in practical.
• Oligonucleotide drug synthesis, purification and quality control technology
Oligonucleotide drug synthesis, purification and quality control is a core
technology of KeyGen. For oligonucleotide drug, the purity over 95% is required
for cancer therapy.
• Oligonucleotide drug delivery technology
For oligonucleotide drug, one obstacle for the therapy effect is that oligonucleotide
drug is difficult to arrive the cancer
cells. KeyGen has developed KeyGenTrans gene
carrier which is a non-virus gene carrier and has proved to be high efficient and
low toxicity.
• In vitro and in vivo anti-cancer drug screening and evaluation technology
KeyGen has setup its own cancer cell bank with over 140 different cancer
cell lines in it and a specific pathogen free (SPF) condition for animal raising
which provide the resources for in vitro and in vivo anti-cancer activity evaluation.
• Cell apoptosis detection technology
Induction of cancer cells to apoptosis is an important strategy for anti-cancer
new drug R&D. KeyGen has the technology of cell apoptosis analysis both at morphological
and quantification level.
Based on the core-technology of KeyGen during the anti-cancer new drug development,
KeyGen has developed series of life science reagents such as the following.
●Cell Biology ------ Series of cell apoptosis detection kits.
●Molecular biology research kits including RT-PCR kits, reverse transcriptase,
Transfection Reagents, etc.
●Protein research kits
● KeyGen cell bank
KeyGen has developed and marketed over 300 different reagents for life science research.
KeyGen’s strong R&D ability has enabled new products continuously added to its
product catalogue. Besides its ability in new products development, KeyGen has setup
the marketing network in the main cities of China which will guarantee KeyGen’s
products to quickly occupy the market. For the next step in life science reagents
market, KeyGen is exploiting the market outside China.
|
|
|
|
|
|
© Copyright 2006 |
|
